ReviewVeterinary medicine and science2025
Co-Occurrence of Ovarian Dysgerminoma-Inducing Gonadoblastoma and Two Distinct Mammary Carcinomas in a Dog: A Case Report and Review of the Literature.
Review in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gonadoblastoma (GB) is an extremely rare mixed gonadal neoplasm, encountered in animals as well as humans. The tumour is typically reported in dysgenetic gonads of those suffering from disorders of sex development and bearing the Y chromosome. Here we highlight the first report of the co-occurrence of an ovarian dysgerminoma-inducing GB and anaplastic and complex carcinomas of distinct mammary glands in a phenotypically normal 12-year-old intact female Spitz lacking the Y chromosome. Germ cells of GB and dysgerminoma were negative for c-kit but immunolabelled with SALL4, OCT-4, and E-cadherin and aberrantly expressed WT-1. Sex cord-stromal cells were immunoreactive for α-inhibin, cytokeratin AE1/AE3, and WT-1. Diffuse vimentin immunostaining was observed, while all cells were negative for high molecular weight cytokeratins. The Ki67 index was 30%. We describe the histopathological and immunohistochemical features of the index case and the polymerase chain reaction analysis of the amelogenin (AMEL) gene and provide a review of the literature. The mechanism of GB development may vary in patients with normal karyotypes and dysgenetic individuals. The WT-1 gene mutation may also play a role in the development of GB in the present case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.